Shock efficacy of the subcutaneous ICD for prevention of sudden cardiac death: Initial multicenter experience

2013 ◽  
Vol 61 (S 01) ◽  
Author(s):  
B Sill ◽  
L Eckardt ◽  
C Butter ◽  
M Schlüter ◽  
K Wegscheider ◽  
...  
Author(s):  
Kevin Willy ◽  
Florian Reinke ◽  
Benjamin Rath ◽  
Christian Ellermann ◽  
Julian Wolfes ◽  
...  

Abstract Aim The subcutaneous ICD (S-ICD) has evolved to a potential first option for many patients who have to be protected from sudden cardiac death. Many trials have underlined a similar performance regarding its effectiveness in relation to transvenous ICDs and have shown the expected benefits concerning infective endocarditis and lead failure. However, there have also been problems due to the peculiarities of the device, such as oversensing and myopotentials. In this study, we present patients from a large tertiary centre suffering from complications with an S-ICD and propose possible solutions. Methods and results All S-ICD patients who experienced complications related to the device (n = 40) of our large-scale single-centre S-ICD registry (n = 351 patients) were included in this study. Baseline characteristics, complications occurring and solutions to these problems were documented over a mean follow-up of 50 months. In most cases (n = 23), patients suffered from oversensing (18 cases with T wave or P wave oversensing, 5 due to myopotentials). Re-programming successfully prevented further oversensing episode in 13/23 patients. In 9 patients, generator or lead-related complications, mostly due to infectious reasons (5/9), occurred. Further problems consisted of ineffective shocks in one patient and need for antibradycardia stimulation in 2 patients and indication for CRT in 2 other patients. In total, the S-ICD had to be extracted in 10 patients. 7 of them received a tv-ICD subsequently, 3 patients refused re-implantation of any ICD. One other patient kept the ICD but had antitachycardic therapy deactivated due to inappropriate shocks for myopotential oversensing. Conclusion The S-ICD is a valuable option for many patients for the prevention of sudden cardiac death. Nonetheless, certain problems are immanent to the S-ICD (limited re-programming options, size of the generator) and should be addressed in future generations of the S-ICD. Graphic abstract


2018 ◽  
Vol 143 (22) ◽  
pp. 1617-1622
Author(s):  
Andreas Napp ◽  
Sebastian Reith

AbstractConventional transvenous pacemaker and ICD-therapy is associated with significant lead- and pocket-related problems. Leadless pacemaker and subcutaneous ICD (S-ICD) therapies are innovative technologies, that avoid these complications. To date two leadless pacemaker systems have been implanted percutaneously for isolated right ventricular pacing, the Nanostim™ and the Micra™ device. The S-ICD represents an alternative to the transvenous ICD for primary and secondary prevention of sudden cardiac death. New multicomponent leadless pacemakers, as well as the combination of leadless pacemaker and S-ICD, are promising therapeutic options in the future. This review describes the state of the art of leadless pacing and S-ICD-therapy.


Sign in / Sign up

Export Citation Format

Share Document